Roche’s sefaxersen shows positive results in kidney disease trial
Roche Holding AG announced that its drug sefaxersen demonstrated positive results in a phase III trial for IgA nephropathy, a kidney disease. The IMAGINATION study, which met its primary endpoint at 37 weeks, showed sefaxersen's potential to be best-in-class in reducing proteinuria compared to placebo. Proteinuria, excess protein in urine, is a critical marker for this condition.
Sefaxersen's safety and tolerability profile remained consistent with prior data, and no new safety concerns emerged during the trial. Roche plans to present interim data at an upcoming medical conference and will share results with regulatory authorities, though no submission timeline was specified.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
